Alex Yurkovetskiy

Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts

Mark D. Walsh, Suzan K. Hanna, Jeremy Sen et al. · Clinical Cancer Research · 2012 · 44 citations

Medicine, Oncology, Pharmacology +14

Synthesis of a Macromolecular Camptothecin Conjugate with Dual Phase Drug Release

Alex Yurkovetskiy, Alexander Hiller, Sadaf Fatima Syed et al. · Molecular Pharmaceutics · 2004 · 39 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer

D. A. Bergstrom, Natalya D. Bodyak, PU Park et al. · Cancer Research · 2016 · 17 citations

Pharmacy, Oncology, Pharmacology +17

Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors

Donald A. Bergstrom, Natalya D. Bodyak, Alex Yurkovetskiy et al. · Cancer Research · 2015 · 15 citations

Pharmacy, Oncology, Pharmacology +15

Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors.

Edward A. Sausville, Lawrence Garbo, Glen J. Weiss et al. · Journal of Clinical Oncology · 2010 · 14 citations

Pharmacy, Pharmacokinetics, Pharmacology +14